Introduction
Polymyositis and dermatomyositis (PM/DM) are systemic autoimmune disorders that involve muscle, skin and lungs. A number of autoantibodies are detected in PM/DM patient sera, some of which are specific to PM/DM (known as myositisspecific autoantibodies; MSAs) or myositis overlap syndromes (known as myositis-associated autoantibodies; MAAs). Notably, each MSA/MAA has characteristic clinical significance, being closely associated with symptoms, complications, reactivity to therapy or prognosis of PM/DM patients. Therefore, identification and measurement of MSAs/MAAs can aid the diagnosis, classification and management of PM/DM patients. The representative MSAs/MAAs are listed in Table 1 . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In this article, we review the clinical significance and the new detection systems for MSAs/MAAs specifically associated with both myositis and interstitial lung disease (ILD).
MSAs associated with ILD in myositis

Among
MSAs/MAAs, anti-aminoacyl-tRNA synthetase (ARS) antibodies and anti-melanoma differentiation-associated gene 5 (MDA5) antibodies have the closest association with ILD in PM/DM. Anti-ARS antibodies are detected in 40-60% of PM/DM-ILD cases [19] [20] [21] and anti-MDA5 in about 25-100% of DM-ILD cases. 19, 21, 22 In our department, 85% of PM/DM-ILD cases were positive for anti-ARS or anti-MDA5 (56% and 29%, respectively). With regard to DM-ILD (including clinically amyopathic DM-ILD), anti-ARS or anti-MDA5 antibodies are detected in about 90% of patients (37% and 52%, respectively). Conversely, 79% of PM-ILD were positive for anti-ARS but anti-MDA5 was not detected (Figure 1 ).
Anti-ARS antibodies
ARSs are enzymes that catalyze the binding of amino acids to the corresponding transfer RNAs to form aminoacyl-tRNAs in an energy-dependent manner. Among the 20 synthetases that correspond to the 20 amino acids, eight different ARSs have been recognized as autoantigens of MSAs, including anti-Jo-1 (histidyl-tRNA synthetase), 23, 24 anti-PL-7 (threonyl), 25 anti-PL-12 (alanyl), 26 anti-EJ (glycyl), 27 anti-OJ (isoleucyl), 28 anti-KS (asparaginyl), 29 anti-tyrosyl-tRNA synthetase antibodies 30 and anti-phenylalanyl-tRNA synthetase antibodies. 31 With a few exceptions, each patient has only one of these autoantibody types; however, patients show similar clinical manifestations, characterized by myositis, ILD, arthritis, fever, Raynaud's phenomenon and mechanic's hand, which is called 'anti-synthetase syndrome (ASS)'. 32 It is noteworthy that ILD is the most prevalent extra-muscular manifestation and is found in 70-95% of anti-ARS-positive patients. [33] [34] [35] ILD of anti-ARS-positive patients tends to be diagnosed at the same time or even before the development of myositis. 32 That is, if anti-ARSs are detected in idiopathic interstitial pneumonia (IIP) patients, some may eventually develop myositis. 20 Indeed, anti-ARS antibodies can be detected in about 5-10% of unselected IIP patients. 35, 36 High resolution computed tomography (HRCT) findings of anti-ARS-positive patients with ILD show predominant involvement of the lower lung fields and the peripheral and/or the peribronchovascular region. Ground-glass opacity (GGO), intralobular reticular opacity, traction bronchiectasis and lower lobe volume loss are frequently observed. 20, 37 These HRCT findings are compatible with a non-specific interstitial pneumonia pattern, whereas the usual interstitial pneumonia pattern showing honeycombing is rare. 20, 35 These characteristics of anti-ARS-positive ILD are common regardless of the presence of PM/ DM. 38 Glucocorticoids are the empirical first-line therapy because both myositis and ILD in anti-ARSpositive patients respond well to initial treatment with glucocorticoids. However, additional immunosuppressive agents are often necessary because both myositis and ILD recur when glucocorticoids are tapered and glucocorticoids are associated with chronic deterioration of muscle strength and pulmonary function. 20, 32, 38 Although anti-ARS-positive patients show similar clinical manifestations with ASS, some detailed clinical analyses suggest some differences in clinical manifestations among patients with different anti-ARS antibodies. Hamaguchi et al. suggested that anti-PL-12, anti-OJ and anti-KS antibodies tended to be associated with ILD rather than myositis. 33 Two other studies showed that arthritis and Table 1 Myositis-specific autoantibodies and myositis-associated autoantibodies.
Autoantibodies
Frequency Significance
Myositis-specific autoantibodies
Anti-aminoacyl-tRNA (ARS) 30% Anti-synthetase syndrome: myositis, ILD, arthritis, Raynaud's phenomenon, fever, mechanic's hand
Severe disease, resistant to treatment, recurrent Anti-Mi-2 4 5-10% Childhood and adult DM Anti-MDA5 (CADM-140) 20-35% of DM CADM, rapidly progressive ILD Anti-TIF1-g [5] [6] [7] 20% of DM DM, malignancy associated DM Anti-NXP2 (MJ) [8] [9] [10] [11] 3-15% DM, JDM, malignancy, skin calcification in children Anti-HMGCR [12] [13] [14] 5-8% Necrotizing myopathy, statin-induced myopathy Anti-SAE 15 myopathy were more frequent in anti-Jo-1 than in non-anti-Jo-1 ARS patients. 39, 40 A meta-analysis also suggested that patients with non-anti-Jo-1 ARS had a greater odds ratio of presenting with fever (relative risk (RR) 0.69, 95% confidence interval (CI) 0.52-0.90) and ILD (RR 0.87, 95% CI 0.81-0.93) than those with anti-Jo-1 antibodies. The frequencies of myositis (RR 1.60, 95% CI 1.38-1.85), arthralgia (RR 1.52, 95% CI 1.32-1.76) and mechanic's hand (RR 1.47, 95% CI 1.11-1.94) were increased by almost 50% in patients with anti-Jo-1 compared to those with non-anti-Jo-1 ARS. 34 Not only clinical manifestations but also mortality appears to be different between anti-Jo-1 and non-Jo-1-anti-synthetase patients. Several reports suggested that non-anti-Jo-1 ARS patients have decreased survival compared with anti-Jo-1 patient. 39, 40 However, this tendency might be explained by the fact that the diagnosis of non-anti-Jo-1-ARS patients tends to be delayed compared with anti-Jo-1 patients, 39 partly because non-anti-Jo-1 ARS antibodies are not detected because validated commercial assays have not been widely available. 39 
Anti-MDA5 antibody
Clinically amyopathic dermatomyositis (CADM) is defined as a disorder with the typical skin manifestations of DM (heliotrope rash or Gottron's papules) but little or no evidence of clinical myositis. It was reported that CADM patients in Asia frequently develop life-threatening, rapidly progressive ILD. 41, 42 In 2005, Sato et al. reported a new autoantibody named anti-CADM-140, which was specific for CADM. 43 Subsequently, the target autoantigen of anti-CADM-140 antibody was identified as MDA5, also known as interferon-induced with helicase C domain protein 1 (IFIH1). 44, 45 Anti-MDA5 is a DM-specific autoantibody that is detected in 20-50% of Asian adult DM patients (including CADM) and is associated with relatively lower creatine kinase (CK) levels, a high frequency of ILD (90-95%), especially rapidly progressive ILD (RP-ILD) (50-80%), and a poor prognosis due to respiratory failure. 43, [45] [46] [47] [48] Interestingly, these characteristics of anti-MDA5-positive patients appear not to be the same in American and European cohorts. [49] [50] [51] [52] The frequency of anti-MDA5 antibodies in American and European cohorts (5-10% in adult DM) is lower than in Asian cohorts. Furthermore, anti-MDA5 antibodies are associated with ILD (60-70%) but not with RP-ILD, in American and European cohorts. 49, 50, 52 Such clinical discrepancies may be explained by differences in ethnicity or environmental background. However, a recent report suggested an association between anti-MDA5 antibodies and RP-ILD even in an American cohort 22 composed of patients with ethnicity similar to the former studies. One of the limitations of these cohort studies of anti-MDA5 is selection bias because the patients were collected from a single centre, and so further international, multicentre investigations are still needed. Gono et al. reported an association between anti-MDA5 positivity and human leukocyte antigen (HLA) DRB1*0101/0405 in a Japanese cohort. 53 Muro et al. reported an increased prevalence of anti-MDA5-positive DM in two areas along the Kiso River in central Japan. 54 Hosono et al. suggested a seasonal occurrence from October to December was associated with the onset of anti-MDA5-positive DM. 55 These findings support the potential influence of genetic and environmental factors on the development of anti-MDA5positive DM.
Anti-MDA5 antibody has also been reported in juvenile dermatomyositis (JDM) cohorts and the clinical characteristics were similar to those of adult patients with anti-MDA5. In Japanese paediatric cohorts, anti-MDA5 was identified in 40-60% of JDM and was associated with ILD, RP-ILD and a poor prognosis. 56, 57 Conversely, in a European cohort, anti-MDA5 was found in 7% of JDM and was associated with skin and mouth ulceration, arthritis and milder muscle disease but was not associated with RP-ILD similar to American adults. 58 Anti-MDA5-positive patients have distinctive features not only in physical manifestations but also in blood tests and radiological findings. Hepatobiliary enzymes and serum ferritin levels were elevated more often in anti-MDA5-positive DM patients than in anti-MDA5-negative DM patients and serum ferritin levels correlated with the activity of ILD in anti-MDA5-positive patients. 54, 59 Moreover, levels of serum cytokines such as interleukin (IL)-6, IL-18 and macrophage colony-stimulating factor are also elevated in anti-MDA5-positive patients. 60, 61 These serological characteristics may indicate the activation of monocytes and macrophages in the pathophysiology of anti-MDA5-positive DM with intractable ILD, although other cytokines, such as IL-8, IL-10 and interferon-a are also elevated, suggesting complex mechanisms in the pathophysiology of the disease. [61] [62] [63] HRCT findings of anti-MDA5-positive patients were reported by Tanizawa et al. as an absence of intralobular reticular opacities and a predominance of consolidation and GGO in lower lung fields or random GGO patterns. 37 Because of the very poor prognosis of DM patients who develop RP-ILD, combined immunosuppressive therapy has been recommended. 64, 65 As anti-MDA5 antibody is strongly associated with RP-ILD and a poor prognosis, we have recently treated anti-MDA5-positive patients with an intensive immunosuppressive regimen including high-dose glucocorticoids, oral calcineurin inhibitors and intravenous cyclophosphamide pulse (Figure 2 ) from the early stage of the disease. This approach achieved an improved survival rate of anti-MDA5-positive patients (Figure 3 ). 66 However, about 25% of anti-MDA5-positive patients did not survive even with this intensive therapy. Therefore, further investigation and establishment of other therapeutic strategies for these DM patients with intractable ILD is still required.
MDA5 is a cytoplasmic retinoic acid-inducible gene- † (RIG- †)-like receptor involved in the recognition of viral RNA leading to the expression of type 1 interferon and inflammatory cytokines. 67 The finding that MDA5 is an autoantigen recognized by a DM-specific autoantibody is interesting because past reports have suggested a potential association between myositis and viral infections, particularly the picornaviruses Coxsackie B virus. [68] [69] [70] Recently, it was suggested that the innate immune response contributes to the pathogenesis of idiopathic inflammatory myopathy, as represented by the Jo-1-induced 71 or the C protein-induced myositis model. 72 Thus, further investigation is required to focus on the relationship between MDA5 and the pathogenesis of DM with intractable ILD to increase our understanding of the pathophysiology of the disease and to develop more effective therapies.
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New detection systems of MSAs
A new ELISA for measuring anti-ARS antibodies
Historically, the detection of anti-ARS antibodies has relied on RNA immunoprecipitation techniques. In this assay, HeLa cell or other tissue culture cell extracts are reacted with patient IgG-bound protein A sepharose beads, and RNA components in the immune complex are extracted, separated on a urea polyacrylamide gel, and visualized by silver staining. 73 This technique is safe and very useful for the screening of autoantibodies to RNA-protein complexes in autoimmune diseases. Anti-ARS antibodies can be identified by the characteristic electrophoretic patterns of transfer RNAs. However, this immunoprecipitation assay can only be performed in restricted laboratories because of its complicated procedure. Other assay systems such as ELISAs (only for anti-Jo-1) and line blots can also be used for detecting anti-ARS antibodies, 74, 75 although all the antibodies of interest are not routinely detected. Thus, we aimed to develop a convenient quantitative ELISA to detect anti-ARS antibodies easily and simultaneously. 35 We isolated cDNAs encoding six major synthetases reactive with autoantibodies (histidyl, threonyl, alanyl, glycyl, isoleucyl and asparaginyl-tRNA synthetases, which correspond to Jo-1, PL-7, PL-12, EJ, OJ and KS, respectively), and made recombinant proteins expressed by Escherichia coli or Hi-5 insect cells. Jo-1, PL-12, EJ and KS were confirmed by reactivity with their corresponding autoantibodies by immunoblot and ELISA, whereas recombinant PL-7 was only detected by ELISA but not by immunoblot. We confirmed that PL-7 had a good reactivity in its native form but not when it was denatured by sodium dodecyl sulfate (SDS) or urea, suggesting that a conformational PL-7 epitope is important for autoantibody reactivity. 35 In contrast, recombinant OJ showed poor antigenic activity even in baculovirus and Figure 3 Survival prognosis of anti-MDA5-positive patients with and without an intensive immunosuppressive regimen. Patients who received an intensive immunosuppressive regimen showed significantly better life prognosis than those who received conventional step-up therapy, 28.6% versus 75.0% of 6 months survival rate. Modified from Nakashima et al. 61 Clinical significance and new detection system of autoantibodies in myositis R Nakashima et al.
Hi-5 cell expression systems or in its native condition. This may be explained by the unique character of isoleucyl-tRNA synthetase, which is a component of a multi-enzyme complex containing eight kinds of class I synthetases and three non-enzymatic factors. 76, 77 Some 'anti-OJ-positive sera' determined by an electrophoretic band pattern of immunoprecipitated proteins might recognize other components or the structural conformation of the complex. Therefore, because we considered it difficult to prepare OJ antigen as a single molecule, we used a mixture of the five recombinant synthetases except for the OJ antigen in a new ELISA system. Investigating the appropriate ratio and concentration of antigens, we found all five anti-ARS antibodies could be detected with the highest sensitivity and specificity in the new ELISA system. Finally, we confirmed the efficacy of the system by screening 694 serum samples from patients with various connective tissue diseases (CTDs) and IIP from a Japanese multicentre study that included 30 healthy controls. Except for one false positive sample, all ELISA results were consistent with the standard RNA immunoprecipitation (sensitivity 100% and specificity 99.8%, compared with RNA immunoprecipitation). 35 Anti-ARS antibodies were detected in 30.8% of PM/DM and 2.5% of other CTDs. Interestingly, anti-ARSs were also positive in 10.7% of IIP patients. 35 Our data suggest that this new ELISA will be useful for the diagnosis and classification of PM/ DM, differential diagnosis of myopathy and ILD, predicting prognosis and deciding the treatment of PM/DM-associated ILD. Moreover, although further investigation will be needed, it might also be useful for monitoring disease activity of PM/DM by quantification of anti-ARS titres. This ELISA system is now manufactured by Medical & Biological Laboratories Co. Ltd. (MBL, Nagoya, Japan), and after a multicentre trial, it was approved for diagnostic use by the health insurance system in Japan in 2014.
The limitation of this assay is the lack of distinguishing each type of anti-ARS antibody. Indeed, as reviewed above, there are some differences in the clinical manifestations and prognosis among patients with different ARS antibodies. However, different treatments for different anti-ARSs have not been established, and anti-ARS-positive patients are treated with the expectation that they share a common pathogenesis and clinical course. Therefore, the ELISA system is an efficient and reasonable method for the detection of anti-ARS as a first screen. A line blot assay for the multiple detection of MSAs/MAAs (EUROLINE Myositis Profile 3, EUROIMMUN, Luebeck, Germany) has been used, in which anti-Jo-1, PL-7, PL-12, EJ and OJ are included as separate analytes. This system can detect and discriminate MSAs/MAAs simultaneously, but it does not include anti-KS, which has a stronger association with IIP than myositis.
Another limitation is our inability to detect anti-OJ antibody by the ELISA, but this may not significantly affect the sensitivity of the assay because the prevalence of anti-OJ is the lowest among the six ARS antibodies. 78 The efficiency of this newly established ELISA system was satisfactory because the sensitivity and specificity of the system compared well with the RNA immunoprecipitation (93.5% and 99.8%, respectively), even if anti-OJpositive sera were not excluded. 35 An ELISA system for measuring anti-MDA5
MSAs that recognize non-RNA-binding proteins can be screened by a protein immunoprecipitation assay using 35 S-methionine-labelled cells as an antigen source. Using this method, anti-MDA5 antibodies are identified by immunoprecipitating the 140 kDa protein. However, this assay is difficult to perform routinely because of the use of radioisotopes and it is technically cumbersome for diagnostic laboratories.
Sato et al. established an ELISA system for efficiently detecting anti-MDA5 antibodies, 44 which used purified, recombinant full-length MDA5 protein expressed in COS-7 cells coated on ELISA plates. The ELISA system had a sensitivity of 85% and specificity of 100% compared with protein immunoprecipitation assay. The authors reported that the ELISA system was useful in diagnosing CADM (sensitivity of 69% and specificity of 99.6%) and predicting RP-ILD (sensitivity of 82% and specificity of 97%). 44 Interestingly, anti-MDA5 titres before treatment tended to be higher in patients with anti-MDA5positive DM with RP-ILD who did not respond to the treatment and died than they were in the patients who responded to therapy and survived. Moreover, the titre of anti-MDA5 antibody was significantly decreased to below the cutoff level after treatment in those who responded to the treatment. 79 For this reason, the ELISA for anti-MDA5 appears to be useful for both the diagnosis of DM as well as in monitoring disease activity and determining the prognosis of anti-MDA5-positive DM with ILD. This ELISA system for anti-MDA5 antibody is commercially available (MBL Co. Ltd., Nagoya, Japan).
Conclusion
In this review, we have highlighted the clinical importance of anti-ARS and anti-MDA5 antibodies in PM/DM with ILD. The newly developed ELISA detection systems are expected to be widely applied in daily practice, but further improvement of the anti-ARS detection system is needed to discriminate between the different anti-ARSs and for the detection of anti-OJ. Anti-ARS and anti-MDA5 antibodies as well as other MSAs have characteristic clinical associations, and their usefulness for the diagnosis, classification and management of PM/ DM is widely recognized. Thus, developing systems to identify other MSAs easily is also required.
